It has been proven that dLNs-targeting therapeutic tumor vaccines can not only significantly increase the CD8+ T cell immune response induced by tumor vaccines, potentially inhibit tumor growth (50), but also help to effectively eliminate metastatic tumor cells in lymph nodes, significantly inhibiting tumor spread (51, 52). The gene discussed is CD8A; the disease is neoplasm.